Ann C. Anselme

Ann C. Anselme

Auto-generated profile, based on publicly available information

Ann C. Anselme

Houston Methodist Research Institute, Houston, TX

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
ACAndrew W. Chung
Andrew W. Chung
Kartik AnandKartik Anand
Kartik Anand
AAAnn C. Anselme
Ann C. Anselme
ACAlfred A. Chan
Alfred A. Chan
NGNakul Gupta
Nakul Gupta
JCJenny C. Chang
Jenny C. Chang
A phase 1/2 clinical trial in patients with chemoresistant triple-negative breast cancer targets the inducible nitric oxide signaling pathway.

8 March 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
ACAndrew W. Chung
Andrew W. Chung
AKAnthony J. Kozielski
Anthony J. Kozielski
WQWei Qian
Wei Qian
JZJianying Zhou
Jianying Zhou
AAAnn C. Anselme
Ann C. Anselme
JCJenny C. Chang
Jenny C. Chang
Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have responded poorly to chemotherapy whereas patients with basal-like 1 (BL1) subtype achieved the best clinical response. In order to gain insight into pathways that may contribute to the divergent sensitivity to chemotherapy, we compared the inflammatory profile of the two TNBC subtypes treated with docetaxel. Cellular signaling analysis determined that docetaxel activated MAPK pathway in MSL TNBCs but not BL1 TNBCs. The subsequent MAPK pathway activation in MSL TNBCs led to an IL-1A mediated cascade of autocrine inflammatory mediators including IL-6. Utilizing the humanized IL-6R antibody, tocilizumab, our in vitro and in vivo data show that MSL TNBCs treated with tocilizumab together with chemotherapy results in delayed tumor progression compared to MSL TNBCs treated with docetaxel alone. Our study highlights a molecular subset of TNBC that may be responsive to tocilizumab therapy for potential translational impact.

15 May 2020 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
TRTejaswini P. Reddy
Tejaswini P. Reddy
DCDong S. Choi
Dong S. Choi
AAAnn C. Anselme
Ann C. Anselme
WQWei Qian
Wei Qian
WCWen Chen
Wen Chen
RRRoberto R. Rosato
Roberto R. Rosato
Background: The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival and development of resistance in response to therapy. This study investigated the effects of Pan-HER (Symphogen, Ballerup, Denmark), a novel mixture of six monoclonal antibodies directed against members of the HER family EGFR, HER2, and HER3, in a preclinical trial of TNBC patient-derived xenografts (PDXs). Methods: Fifteen low passage TNBC PDX tumor samples were transferred into the right mammary fat pad of mice for engraftment. When tumors reached an average size of 100–200 mm3, mice were randomized (n ≥ 6 per group) and treated following three 1-week cycles consisting of three times/week intraperitoneal (IP) injection of either formulation buffer (vehicle control) or Pan-HER (50 mg/kg). At the end of treatment, tumors were collected for Western blot, RNA, and immunohistochemistry analyses. Results: All 15 TNBC PDXs were responsive to Pan-HER treatment, showing significant reductions in tumor growth consistent with Pan-HER-mediated tumor downmodulation of EGFR and HER3 protein levels and significantly decreased activation of associated HER family signaling pathways AKT and ERK. Tumor regression was observed in five of the models, which corresponded to those PDX tumor models with the highest level of HER family activation. Conclusions: The marked effect of Pan-HER in numerous HER family-dependent TNBC PDX models justifies further studies of Pan-HER in TNBC clinical trials as a potential therapeutic option.

4 April 2023 in Cancer Research
Verified
Journal Article
Closed access
IUIvonne Uzair
Ivonne Uzair
KSKai Sun
Kai Sun
AAAnn Anselme
Ann Anselme
WQWei Qian
Wei Qian
JZJianying Zhou
Jianying Zhou
JCJenny Chang
Jenny Chang
Purpose of the study: To evaluate the role of obesity in tumor progression and tumor microenvironment (TME) dynamic after the inhibition of nitric oxide synthase (NOS) in syngeneic murine models engrafted with triple negative breast cancer (TNBC) tumors. For this study, we wanted to deepen the results of our recently completed phase I/II clinical trial, where treatment with NG-methyl-L-arginine (L-NMMA, a pan-NOS inhibitor) increased the response rate to chemotherapy (docetaxel) in obese metastatic TNBC (ER-/PR-/HER2-) patients to 86% vs. 60% in normal weight individuals. TME analysis from responders revealed a neutrophil phenotype shift from protumor N2 to antitumor N1. We thus hypothesize that combined treatment with L-NMMA and docetaxel enhances antitumor effect by modulating TME in obese mice with TNBC. Experimental procedures: 3-week old female C57BL/6 mice were fed for 10 weeks either with high fat diet (HFD) or normal diet (ND). At week 13, TNBC mouse E0771 tumor cells were injected into the mice mammary fat pad. Once tumors reached 100 mm3, the animals were randomized to four groups: vehicle; docetaxel; L-NMMA; and docetaxel plus L-NMMA treatment. Tumor volume was measured throughout the experiment and growth rate was compared between groups at the end of treatment. Blood, tumor and perigonadal white adipose tissue (pgWAT) were collected. Cytokines and nitrite/nitrate levels (NO2-/NO3-, a NO indicator) were measured from blood and conditioned media (CM) from pgWAT using appropriate kits. Tumor immune cell infiltration was evaluated by immunohistochemistry. GraphPad software was used for statistical analysis and P-values <0.05 were considered to describe statistically significant differences between groups. Results: Tumor growth rate was significantly higher in HFD mice compared to ND mice. Treatment with the docetaxel/L-NMMA combination significantly slowed tumor growth in HFD mice (p=0.015), and showed a similar trend in ND mice (p=0.92) vs. the corresponding vehicle-treated groups. The reduction of tumor growth was significantly higher in HFD mice vs. ND mice (median of differences -2.0, p=0.031). HFD mice presented higher levels of pro-inflammatory cytokines, [IL-1b (p=0.011), IL-6 (p<0.0001) and TNFa (p<0.0001)] vs ND mice in pgWAT CM, as well as increased levels of NO2-/NO3- and expression of iNOS in tumors and in perigonadal adipose tissue. Conclusion: HFD mice had a pro-inflammatory profile with a significantly faster tumor growth and higher expression of iNOS in tumor and adipose tissues. Treatment with the docetaxel/L-NMMA combination resulted in a more significant anti-tumor effect in HFD mice, likely through remodeling of TME. Spatial analysis, including CODEX and immunophenotyping are being conducted to determine the TME influence in obesity associated TNBC and the effect of NOS inhibition. Citation Format: Ivonne Uzair, Kai Sun, Ann Anselme, Wei Qian, Jianying Zhou, Roberto Rosato, Jenny Chang. NOS inhibition enhances docetaxel-mediated anti-tumor effect in obese mice with triple negative breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3991.

16 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
IUIvonne D. Uzair
Ivonne D. Uzair
ABAgne Baseviciene
Agne Baseviciene
JDJenying Deng
Jenying Deng
RBRecep Bayraktar
Recep Bayraktar
AAAnn C. Anselme
Ann C. Anselme
JCJenny C. Chang
Jenny C. Chang
Obesity is associated with increased incidence and mortality in triple-negative breast cancer, however, the tumor-intrinsic mechanisms driving obesity-associated tumor progression remain poorly understood. Here, we identify the role of inducible nitric oxide synthase as a redox-active mediator that modulates obesity-associated inflammation and remodels the tumor microenvironment into an immunosuppressive state. iNOS expression was elevated in TNBC compared to other breast cancer subtypes and was associated with shorter overall survival, and obese TNBC patients preferentially benefited from iNOS inhibition combined with chemotherapy. In syngeneic TNBC models of diet-induced obesity, high-fat diet increased tumor growth and iNOS expression. Obesity-conditioned adipocytes induced tumor-cell iNOS expression and promoted iNOS-dependent production of the monocyte-recruiting chemokine CCL2. Tumor-specific deletion of iNOS abolished obesity-driven tumor progression and reprogrammed the tumor immune compartment by reducing recruitment of monocytic myeloid-derived suppressor cells, restoring antigen-presenting M1-like macrophages, and rescuing the tissue-resident memory-like cytotoxic T-cell population. Treatment with the pan-NOS inhibitor L-NMMA selectively enhanced the antitumor activity of docetaxel in obese, but not lean, tumor-bearing mice, and shifted the immune landscape of obese tumors toward that of lean controls. Together, these findings establish tumor-intrinsic iNOS as a key mediator of the obese tumor microenvironment through sustained nitric oxide signaling that promotes myeloid remodeling and impairs anti-tumor immunity. These results provide a strong rationale for clinical evaluation of iNOS-targeting strategies to enhance chemotherapy response, particularly in patients with obesity and TNBC.